Clinical research in Brazil – New horizons, new challenges
Unraveling the Abbreviated Development Path
COVID-19: What facilities is ANVISA providing at this time of crisis?
Why are 24% of drug registrations still rejected?
API, BPF and drug dossier - How to align the processes to ensure success in registration?
NEW API REGULATORY FRAMEWORK: Will ANVISA and international manufacturers be prepared?
Publication of the new API regulatory framework: what is essential to know?
